KRAS G12C and Beyond: KRAS Targeted Agents of Interest Under Development in NSCLC
Benjamin Herzberg, MD, highlights novel therapies in the KRAS-mutated NSCLC landscape and ongoing questions research is seeking to answer in this space.
Related Articles
Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC
Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.
Targeted CAR T-Cell Therapies Show Early Efficacy in Solid Tumors With Focus on Mitigating Toxicity
Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell agents in patients with solid tumors.
Post Hoc Data Show Anemia Benefits, Reduced Transfusion Burden With Momelotinib in Myelofibrosis
Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.
Post Hoc Data Show Anemia Benefits, Reduced Transfusion Burden With Momelotinib in Myelofibrosis
Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.
First-Line Penpulimab Plus Chemo Extends PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma
Penpulimab plus chemotherapy improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma.
Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC
Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.
Zongertinib Could Alter SOC in HER2-Mutated Advanced NSCLC
John V. Heymach, MD, PhD, discusses updated findings from the phase 1b Beamion LUNG-1 trial of zongertinib in HER2-mutated advanced NSCLC.
The OncFive: Top Oncology Articles for the Week of 5/11
The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.
Adjuvant Aumolertinib Boosts DFS in Stage II-IIIB, EGFR-Mutated NSCLC
Adjuvant aumolertinib improved disease-free survival in complete resected stage II to IIIB non–small cell lung cancer harboring EGFR mutations.
FDA Grants Fast Track Designation to BI-1808 in Select Cutaneous T-Cell Lymphoma
BI-1808 has received FDA fast track designation for the treatment of patients with select cutaneous T-cell lymphoma subtypes.